A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia

Published:2018-09-23 Issue:1 Volume:66 Page:e27458
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Kloos Robin Q. H.¹^ORCID,van Litsenburg Raphaële R. L.²,Wolf Sarah³,Wismans Leonoor¹,Kaspers Gertjan J. L.²,Uyl-de Groot Carin A.³,Pieters Rob²,van der Sluis Inge M.²

Affiliation:

1. Department of Pediatric Oncology and Hematology; Erasmus MC - Sophia Children's Hospital; Rotterdam The Netherlands

2. Princess Máxima Center for Pediatric Oncology; Utrecht The Netherlands

3. Institute of Health Care Policy & Management/Institute for Medical Technology Assessment Erasmus University; Rotterdam The Netherlands

Funder

Stichting Kinderen Kankervrij

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.27458/fullpdf

Reference19 articles.

1. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study;Amylon;Leukemia,1999

2. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial;Duval;Blood,2002

3. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia;Moghrabi;Blood,2007

4. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia;Pession;J Clin Oncol,2005

5. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group;Pieters;J Clin Oncol,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial;Journal of Clinical Oncology;2024-05-10

2. Healthcare costs of cancer among children, adolescents, and young adults: A scoping review;Cancer Medicine;2024-01-12

3. Extracellular expression of Saccharomyces cerevisiae’s L-asparaginase II in Pichia pastoris results in novel enzyme with better parameters;Preparative Biochemistry & Biotechnology;2022-08-18

4. Optimizing pegaspargase therapy in patients with hypersensitivity reactions;Leukemia & Lymphoma;2022-06-21

5. Asparaginase encapsulated in erythrocytes as second‐line treatment in hypersensitive patients with acute lymphoblastic leukaemia;British Journal of Haematology;2022-03-28